<VariationArchive VariationID="812481" VariationName="NM_177924.5(ASAH1):c.594_599dup (p.Phe199_Lys200insAsnPhe)" VariationType="Duplication" Accession="VCV000812481" Version="1" RecordType="classified" NumberOfSubmissions="1" NumberOfSubmitters="1" DateLastUpdated="2024-05-08" DateCreated="2020-02-16" MostRecentSubmission="2020-02-16">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="800727" VariationID="812481">
      <GeneList>
        <Gene Symbol="ASAH1" FullName="N-acylsphingosine amidohydrolase 1" GeneID="427" HGNC_ID="HGNC:735" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>8p22</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="8" Accession="NC_000008.11" start="18055992" stop="18084961" display_start="18055992" display_stop="18084961" Strand="-" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="8" Accession="NC_000008.10" start="17913924" stop="17942506" display_start="17913924" display_stop="17942506" Strand="-" />
          </Location>
          <OMIM>613468</OMIM>
        </Gene>
      </GeneList>
      <Name>NM_177924.5(ASAH1):c.594_599dup (p.Phe199_Lys200insAsnPhe)</Name>
      <CanonicalSPDI>NC_000008.11:18062327:TTGAAG:TTGAAGTTGAAG</CanonicalSPDI>
      <VariantType>Duplication</VariantType>
      <Location>
        <CytogeneticLocation>8p22</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="8" Accession="NC_000008.11" start="18062327" stop="18062328" display_start="18062327" display_stop="18062328" variantLength="6" positionVCF="18062327" referenceAlleleVCF="C" alternateAlleleVCF="CTTGAAG" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="8" Accession="NC_000008.10" start="17919836" stop="17919837" display_start="17919836" display_stop="17919837" variantLength="6" positionVCF="17919836" referenceAlleleVCF="C" alternateAlleleVCF="CTTGAAG" />
      </Location>
      <HGVSlist>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_177924.5" sequenceAccession="NM_177924" sequenceVersion="5" change="c.594_599dupCTTCAA" MANESelect="true">
            <Expression>NM_177924.5:c.594_599dupCTTCAA</Expression>
          </NucleotideExpression>
          <MolecularConsequence ID="SO:0001821" Type="inframe_insertion" DB="SO" />
        </HGVS>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000008.10" sequenceAccession="NC_000008" sequenceVersion="10" change="g.17919837_17919842dup" Assembly="GRCh37">
            <Expression>NC_000008.10:g.17919837_17919842dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000008.11" sequenceAccession="NC_000008" sequenceVersion="11" change="g.18062328_18062333dup" Assembly="GRCh38">
            <Expression>NC_000008.11:g.18062328_18062333dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_008985.2" sequenceAccession="NG_008985" sequenceVersion="2" change="g.27666_27671dup">
            <Expression>NG_008985.2:g.27666_27671dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001127505.3" sequenceAccession="NM_001127505" sequenceVersion="3" change="c.576_581dup">
            <Expression>NM_001127505.3:c.576_581dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001120977.1" sequenceAccession="NP_001120977" sequenceVersion="1" change="p.Phe193_Lys194insAsnPhe">
            <Expression>NP_001120977.1:p.Phe193_Lys194insAsnPhe</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001821" Type="inframe_insertion" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001363743.2" sequenceAccession="NM_001363743" sequenceVersion="2" change="c.399_404dup">
            <Expression>NM_001363743.2:c.399_404dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001350672.1" sequenceAccession="NP_001350672" sequenceVersion="1" change="p.Phe134_Lys135insAsnPhe">
            <Expression>NP_001350672.1:p.Phe134_Lys135insAsnPhe</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001821" Type="inframe_insertion" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_004315.6" sequenceAccession="NM_004315" sequenceVersion="6" change="c.642_647dup">
            <Expression>NM_004315.6:c.642_647dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_004306.3" sequenceAccession="NP_004306" sequenceVersion="3" change="p.Phe215_Lys216insAsnPhe">
            <Expression>NP_004306.3:p.Phe215_Lys216insAsnPhe</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001821" Type="inframe_insertion" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_177924.5" sequenceAccession="NM_177924" sequenceVersion="5" change="c.594_599dup" MANESelect="true">
            <Expression>NM_177924.5:c.594_599dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_808592.2" sequenceAccession="NP_808592" sequenceVersion="2" change="p.Phe199_Lys200insAsnPhe">
            <Expression>NP_808592.2:p.Phe199_Lys200insAsnPhe</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001821" Type="inframe_insertion" DB="SO" />
        </HGVS>
      </HGVSlist>
      <XRefList>
        <XRef Type="rs" ID="1588978684" DB="dbSNP" />
      </XRefList>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_177924.5(ASAH1):c.594_599dup (p.Phe199_Lys200insAsnPhe) AND multiple conditions" Accession="RCV001003310" Version="2">
        <ClassifiedConditionList TraitSetID="12756">
          <ClassifiedCondition DB="MedGen" ID="C0268255">Farber lipogranulomatosis</ClassifiedCondition>
          <ClassifiedCondition DB="MedGen" ID="C1834569">Spinal muscular atrophy-progressive myoclonic epilepsy syndrome</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2019-06-19" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2019-06-19" NumberOfSubmissions="1" NumberOfSubmitters="1" DateCreated="2020-02-16" MostRecentSubmission="2020-02-16">
        <ReviewStatus>criteria provided, single submitter</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <ID Source="DOI">10.1542/peds.2016-1068</ID>
        </Citation>
        <ConditionList>
          <TraitSet ID="12756" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="14121" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Farber's lipogranulomatosis</ElementValue>
                <XRef ID="79935000" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Farber's disease</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Farber disease</ElementValue>
                <XRef ID="333" DB="Orphanet" />
              </Name>
              <Name>
                <ElementValue Type="Preferred">Farber lipogranulomatosis</ElementValue>
                <XRef ID="MONDO:0009218" DB="MONDO" />
                <XRef ID="79935000" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Ceramidase deficiency</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Acid ceramidase deficiency</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">AC deficiency</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">N-Laurylsphingosine deacylase deficiency</ElementValue>
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">FRBRL</ElementValue>
                <XRef Type="MIM" ID="228000" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">The spectrum of ASAH1-related disorders ranges from Farber disease (FD) to spinal muscular atrophy with progressive myoclonic epilepsy (SMA-PME). Classic FD is characterized by onset in the first weeks of life of painful, progressive deformity of the major joints; palpable subcutaneous nodules of joints and mechanical pressure points; and a hoarse cry resulting from granulomas of the larynx and epiglottis. Life expectancy is usually less than two years. In the other less common types of FD, onset, severity, and primary manifestations vary. SMA-PME is characterized by early-childhood-onset progressive lower motor neuron disease manifest typically between ages three and seven years as proximal lower-extremity weakness, followed by progressive myoclonic and atonic seizures, tremulousness/tremor, and sensorineural hearing loss. Myoclonic epilepsy typically begins in late childhood after the onset of weakness and can include jerking of the upper limbs, action myoclonus, myoclonic status, and eyelid myoclonus. Other findings include generalized tremor, and cognitive decline. The time from disease onset to death from respiratory complications is usually five to 15 years.</Attribute>
                <XRef ID="NBK488189" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="6426" />
                <XRef ID="6426" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">29595935</ID>
                <ID Source="BookShelf">NBK488189</ID>
              </Citation>
              <XRef ID="333" DB="Orphanet" />
              <XRef ID="C0268255" DB="MedGen" />
              <XRef ID="MONDO:0009218" DB="MONDO" />
              <XRef Type="MIM" ID="228000" DB="OMIM" />
            </Trait>
            <Trait ID="5587" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">MYOCLONUS, HEREDITARY, WITH PROGRESSIVE DISTAL MUSCULAR ATROPHY</ElementValue>
                <XRef Type="MIM" ID="159950" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">SPINAL MUSCULAR ATROPHY WITH PROGRESSIVE MYOCLONIC EPILEPSY</ElementValue>
                <XRef Type="MIM" ID="159950" DB="OMIM" />
                <XRef Type="Allelic variant" ID="613468.0006" DB="OMIM" />
                <XRef Type="Allelic variant" ID="613468.0011" DB="OMIM" />
                <XRef Type="Allelic variant" ID="613468.0007" DB="OMIM" />
                <XRef Type="Allelic variant" ID="613468.0010" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Jankovic Rivera syndrome</ElementValue>
                <XRef ID="Jankovic+Rivera+syndrome/3897" DB="Genetic Alliance" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Hereditary myoclonus and progressive distal muscular atrophy</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">Spinal muscular atrophy-progressive myoclonic epilepsy syndrome</ElementValue>
                <XRef ID="MONDO:0008045" DB="MONDO" />
              </Name>
              <Symbol>
                <ElementValue Type="Alternate">SMAPME</ElementValue>
                <XRef Type="MIM" ID="159950" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="3875" />
                <XRef ID="3875" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">The spectrum of ASAH1-related disorders ranges from Farber disease (FD) to spinal muscular atrophy with progressive myoclonic epilepsy (SMA-PME). Classic FD is characterized by onset in the first weeks of life of painful, progressive deformity of the major joints; palpable subcutaneous nodules of joints and mechanical pressure points; and a hoarse cry resulting from granulomas of the larynx and epiglottis. Life expectancy is usually less than two years. In the other less common types of FD, onset, severity, and primary manifestations vary. SMA-PME is characterized by early-childhood-onset progressive lower motor neuron disease manifest typically between ages three and seven years as proximal lower-extremity weakness, followed by progressive myoclonic and atonic seizures, tremulousness/tremor, and sensorineural hearing loss. Myoclonic epilepsy typically begins in late childhood after the onset of weakness and can include jerking of the upper limbs, action myoclonus, myoclonic status, and eyelid myoclonus. Other findings include generalized tremor, and cognitive decline. The time from disease onset to death from respiratory complications is usually five to 15 years.</Attribute>
                <XRef ID="NBK488189" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">29595935</ID>
                <ID Source="BookShelf">NBK488189</ID>
              </Citation>
              <XRef ID="2590" DB="Orphanet" />
              <XRef ID="C1834569" DB="MedGen" />
              <XRef ID="MONDO:0008045" DB="MONDO" />
              <XRef Type="MIM" ID="159950" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="2288690" SubmissionDate="2019-07-15" DateLastUpdated="2020-02-16" DateCreated="2020-02-16">
        <ClinVarSubmissionID localKey="Pt 28.1 NM_177924.5(ASAH1):c.594_599dupCTTCAA" localKeyIsSubmitted="1" submittedAssembly="not applicable" />
        <ClinVarAccession Accession="SCV001161394" DateUpdated="2020-02-16" DateCreated="2020-02-16" Type="SCV" Version="1" SubmitterName="Medical Affairs, Dicerna Pharmaceuticals" OrgID="507035" OrganizationCategory="other" OrgAbbreviation="MA" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2019-06-19">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="DOI">10.1542/peds.2016-1068</ID>
          </Citation>
          <Comment>The clinical significance of variant c.594_599dupCTTCAA is pathogenic based on the following rationale. This patient described in Teoh et al., 2017, DOI: 10.1542/peds.2016-1068, presented with a unique combined Farber disease/SMA-PME phenotype as described by Gene Reviews (https://www.ncbi.nlm.nih.gov/books/NBK488189/). Whole exome sequencing revealed compound heterozygous variants, c.518A&gt;T and c.594_599dupCTTCAA, in the ASAH1 gene. The mutation, c.594_599dupCTTCAA, was Sanger sequenced for confirmation and each parent was found to carry one of the variants supporting autosomal recessive inheritance with a compound heterozygous model. Acid ceramidase level was carried out by using a leukocyte assay in the laboratory of Professor Edward Schuchman, at Mount Sinai, NY, and showed significantly decreased levels of acid ceramidase activity when compared with that of the parents lending to the verification of pathogenicity in this variant.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="ModeOfInheritance">Autosomal recessive inheritance</Attribute>
        </AttributeSet>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>inherited</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>yes</AffectedStatus>
              <FamilyData NumFamiliesWithSegregationObserved="1" NumFamiliesWithVariant="1">
                <FamilyHistory>yes</FamilyHistory>
              </FamilyData>
            </Sample>
            <Method>
              <Description>Whole exome sequencing; Sanger sequencing; in silico analysis</Description>
              <MethodType>literature only</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="VariantAlleles" integerValue="1" />
            </ObservedData>
            <ObservedData>
              <Attribute Type="SecondaryFinding">no</Attribute>
            </ObservedData>
            <TraitSet Type="Finding">
              <Trait Type="Finding" ClinicalFeaturesAffectedStatus="present">
                <Name>
                  <ElementValue Type="Preferred">joint stiffness</ElementValue>
                </Name>
              </Trait>
              <Trait Type="Finding" ClinicalFeaturesAffectedStatus="present">
                <Name>
                  <ElementValue Type="Preferred">swelling</ElementValue>
                </Name>
              </Trait>
              <Trait Type="Finding" ClinicalFeaturesAffectedStatus="present">
                <Name>
                  <ElementValue Type="Preferred">pain</ElementValue>
                </Name>
              </Trait>
              <Trait Type="Finding" ClinicalFeaturesAffectedStatus="present">
                <Name>
                  <ElementValue Type="Preferred">progressive muscle weakness</ElementValue>
                </Name>
              </Trait>
              <Trait Type="Finding" ClinicalFeaturesAffectedStatus="present">
                <Name>
                  <ElementValue Type="Preferred">amyotrophy</ElementValue>
                </Name>
              </Trait>
              <Trait Type="Finding" ClinicalFeaturesAffectedStatus="present">
                <Name>
                  <ElementValue Type="Preferred">chronic and active denervation consistent with motor neuropathy/neuronopathy</ElementValue>
                </Name>
              </Trait>
              <Trait Type="Finding" ClinicalFeaturesAffectedStatus="present">
                <Name>
                  <ElementValue Type="Preferred">bulbar dysfunction emerged</ElementValue>
                </Name>
              </Trait>
              <Trait Type="Finding" ClinicalFeaturesAffectedStatus="present">
                <Name>
                  <ElementValue Type="Preferred">tongue fasciculations</ElementValue>
                </Name>
              </Trait>
              <Trait Type="Finding" ClinicalFeaturesAffectedStatus="present">
                <Name>
                  <ElementValue Type="Preferred">atrophy</ElementValue>
                </Name>
              </Trait>
              <Trait Type="Finding" ClinicalFeaturesAffectedStatus="present">
                <Name>
                  <ElementValue Type="Preferred">uncoordinated swallow</ElementValue>
                </Name>
              </Trait>
              <Trait Type="Finding" ClinicalFeaturesAffectedStatus="present">
                <Name>
                  <ElementValue Type="Preferred">recurrent aspiration pneumonia</ElementValue>
                </Name>
              </Trait>
              <Trait Type="Finding" ClinicalFeaturesAffectedStatus="present">
                <Name>
                  <ElementValue Type="Preferred">cognitive decline</ElementValue>
                </Name>
              </Trait>
              <Trait Type="Finding" ClinicalFeaturesAffectedStatus="present">
                <Name>
                  <ElementValue Type="Preferred">memory disturbance</ElementValue>
                </Name>
              </Trait>
              <Trait Type="Finding" ClinicalFeaturesAffectedStatus="present">
                <Name>
                  <ElementValue Type="Preferred">hoarse voice</ElementValue>
                </Name>
              </Trait>
              <Trait Type="Finding" ClinicalFeaturesAffectedStatus="present">
                <Name>
                  <ElementValue Type="Preferred">mild intellectual impairment</ElementValue>
                </Name>
              </Trait>
            </TraitSet>
          </ObservedIn>
          <ObservedIn>
            <Sample>
              <Origin>inherited</Origin>
              <Tissue>white blood cells</Tissue>
              <Species TaxonomyId="9606">Human</Species>
              <AffectedStatus>yes</AffectedStatus>
            </Sample>
            <Method>
              <Purpose>assert pathogenicity</Purpose>
              <Description>Acid ceramidase level was carried out by using a leukocyte assay in the laboratory of Professor Edward Schuchman, at Mount Sinai, NY.</Description>
              <MethodType>literature only</MethodType>
              <ObsMethodAttribute>
                <Attribute Type="MethodResult">Showed significantly decreased levels of acid ceramidase activity when compared with that of the parents. These levels correlated with those previously seen in patients who were severely affected by Farber disease tested by the same laboratory.</Attribute>
              </ObsMethodAttribute>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
            <Citation>
              <ID Source="DOI">10.1542/peds.2016-1068</ID>
            </Citation>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="ASAH1" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_177924.5:c.594_599dupCTTCAA</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="228000" Type="MIM" />
          </Trait>
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="159950" Type="MIM" />
          </Trait>
        </TraitSet>
        <Comment>Deletions or mutations were not identified in survival of motor neuron 1 by molecular testingThe mutations were Sanger sequenced for confirmation and each parent was found to carry one of the variants supporting autosomal recessive inheritance with a compound heterozygous model. Genetic testing for SMN1 mutations or deletions. Whole exome sequencing was carried out at the University of Washington Genome Center. Sanger sequencing was performed to confirm the mutations in proband and for segregation analysis in family members. The initial whole exome sequencing data analysis confirmed several hundred rare variants with an allele frequency of &lt;1% in control databases. Only 2 genes had at least 2 rare variants within the coding sequence when analyzed for a potential compound heterozygous model, ASAH1 and UBQLN1. Only the variants in ASAH1 had consistent pathogenicity analyses, including an inframe insertion, (c.502G&gt;T) (c.594_599dupCTTCAA).</Comment>
        <SubmissionNameList>
          <SubmissionName>SUB5958214</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="2288690" TraitType="Finding" MappingType="Name" MappingValue="mild intellectual impairment" MappingRef="Preferred">
        <MedGen CUI="None" Name="mild intellectual impairment" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="2288690" TraitType="Finding" MappingType="Name" MappingValue="tongue fasciculations" MappingRef="Preferred">
        <MedGen CUI="C0239548" Name="Tongue fasciculations" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="2288690" TraitType="Finding" MappingType="Name" MappingValue="recurrent aspiration pneumonia" MappingRef="Preferred">
        <MedGen CUI="C0747651" Name="Recurrent aspiration pneumonia" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="2288690" TraitType="Finding" MappingType="Name" MappingValue="progressive muscle weakness" MappingRef="Preferred">
        <MedGen CUI="C0240421" Name="Progressive muscle weakness" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="2288690" TraitType="Finding" MappingType="Name" MappingValue="uncoordinated swallow" MappingRef="Preferred">
        <MedGen CUI="None" Name="uncoordinated swallow" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="2288690" TraitType="Finding" MappingType="Name" MappingValue="pain" MappingRef="Preferred">
        <MedGen CUI="C0030193" Name="Pain" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="2288690" TraitType="Finding" MappingType="Name" MappingValue="bulbar dysfunction emerged" MappingRef="Preferred">
        <MedGen CUI="None" Name="bulbar dysfunction emerged" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="2288690" TraitType="Disease" MappingType="XRef" MappingValue="159950" MappingRef="OMIM">
        <MedGen CUI="C1834569" Name="Spinal muscular atrophy-progressive myoclonic epilepsy syndrome" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="2288690" TraitType="Finding" MappingType="Name" MappingValue="hoarse voice" MappingRef="Preferred">
        <MedGen CUI="C0019825" Name="Hoarse voice" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="2288690" TraitType="Finding" MappingType="Name" MappingValue="swelling" MappingRef="Preferred">
        <MedGen CUI="C0038999" Name="swelling" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="2288690" TraitType="Finding" MappingType="Name" MappingValue="chronic and active denervation consistent with motor neuropathy/neuronopathy" MappingRef="Preferred">
        <MedGen CUI="None" Name="chronic and active denervation consistent with motor neuropathy/neuronopathy" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="2288690" TraitType="Finding" MappingType="Name" MappingValue="memory disturbance" MappingRef="Preferred">
        <MedGen CUI="C0233794" Name="Memory impairment" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="2288690" TraitType="Disease" MappingType="XRef" MappingValue="228000" MappingRef="OMIM">
        <MedGen CUI="C0268255" Name="Farber lipogranulomatosis" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="2288690" TraitType="Finding" MappingType="Name" MappingValue="joint stiffness" MappingRef="Preferred">
        <MedGen CUI="C0162298" Name="Joint stiffness" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="2288690" TraitType="Finding" MappingType="Name" MappingValue="atrophy" MappingRef="Preferred">
        <MedGen CUI="C0333641" Name="Atrophy" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="2288690" TraitType="Finding" MappingType="Name" MappingValue="cognitive decline" MappingRef="Preferred">
        <MedGen CUI="C0234985" Name="Mental deterioration" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="2288690" TraitType="Finding" MappingType="Name" MappingValue="amyotrophy" MappingRef="Preferred">
        <MedGen CUI="C0541794" Name="Muscular atrophy" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

